| Systematic (IUPAC) name | |
|---|---|
| 2-(5-methoxy-2-methyl-H-indol-3-yl)-N,N-dimethylethanamine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 67292-68-6 |
| ATC code | ? |
| PubChem | CID 49756 |
| ChemSpider | 45143 |
| ChEMBL | CHEMBL7143 |
| Chemical data | |
| Formula | C14H20N2O |
| Mol. mass | 232.321 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
5-Methoxy-2,N,N-trimethyltryptamine (5-MeO-2,N,N-TMT, 5-MeO-TMT) is a psychoactive drug of the tryptamine chemical class which acts as a psychedelic. It was first synthesized by Alexander Shulgin and reported in his book TiHKAL ("Tryptamines i Have Known And Loved").[1] 5-MeO-TMT is claimed to show psychoactive effects at a dosage of 75-150 mg orally, but these are relatively mild compared to those of other similar compounds. This suggests that while the methyl group on the 2-position of the molecule has impaired the binding of metabolic enzymes like monoamine oxidase (MAO), it is also interfering with binding to and/or activation of the serotonin 5-HT2A receptor, the target responsible for mediating the hallucinogenic effects of such compounds.
|
||||||||||||||||||||||||||||||||||
|
|||||